Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 03:59:59 2024-02-27 pm EST 5-day change 1st Jan Change
278.5 USD -2.76% Intraday chart for Amgen Inc. -1.77% -3.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stocks stall as key inflation data awaited RE
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
US STOCK-Wall Street wavers ahead of key inflation data RE
Amgen Opens Manufacturing Site in Central Ohio MT
Transcript : Amgen Inc. - Special Call
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
Amazon replaces Walgreens on Dow Jones index RE
Transcript : Amgen Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-14-2024 12:00 PM
Eli Lilly partner BioAge raises $170 mln for obesity treatment RE
Global markets live: Amgen, Chipotle, Ford, Gilead, VF Corp... Our Logo
Abivax appoints new head of quality CF
Fed officials fail to convince investors, who are focused on earnings Our Logo
Oppenheimer Adjusts Amgen Price Target to $380 From $350, Maintains Outperform Rating MT
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15 DP
TD Cowen Adjusts Amgen Price Target to $370 From $336, Maintains Outperform Rating MT
Leerink Partners Downgrades Amgen to Market Perform From Outperform, Adjusts Price Target to $324 From $318 MT
Baird Adjusts Amgen Price Target to $215 From $185, Maintains Underperform Rating MT
Goldman Sachs Adjusts Amgen Price Target to $350 From $313, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Amgen to $278 From $281 After Higher-Than-Expected Q4 2023 Results, Keeps Equalweight Rating MT
RBC Boosts Price Target on Amgen to $329 From $303 After Q4 Beats, Notes 'Positive' Pipeline Posture; Keeps Outperform Rating MT
Stock Futures Uneven Pre-Bell as Traders Digest Latest Round of Earnings; Asia Churns, Europe Falls MT
News Highlights : Top Company News of the Day - Wednesday at 5 AM ET DJ
Amgen: EPS up 15% in Q4 CF
Amgen 4Q Revenue Surges as Acquisition Boosts Results DJ
Amgen Q4 Non-GAAP Earnings, Revenue Rise; Full-Year 2024 Guidance Set MT
Chart Amgen Inc.
More charts
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
278.5 USD
Average target price
303.6 USD
Spread / Average Target
+9.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq
  4. News Amgen Inc.
  5. Amgen Insider Sold Shares Worth $572,276, According to a Recent SEC Filing
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW